Lärkberget (LARK) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
22 Aug, 2025Executive summary
Completed a strategic transformation from research to investment focus, including a name change and full divestment of research activities.
New leadership appointed: Luca Di Stefano as interim CEO and Robert Klatzkow as chairman.
Foundation laid for initial investments, with a focus on long-term value creation and risk-adjusted returns.
Dividend of 0.20 SEK per share (3.96 MSEK) distributed in June 2025.
Financial highlights
Net sales for Jan–Jun 2025: 252 TSEK (992 TSEK Jan–Jun 2024).
Result after financial items: -12,339 TSEK (-8,403 TSEK Jan–Jun 2024), mainly due to costs from winding down research.
Cash flow for the period: -13,466 TSEK (-17,796 TSEK Jan–Jun 2024).
Cash and cash equivalents at period end: 60,282 TSEK (83,553 TSEK Jun 2024).
Equity per share: 2.79 SEK (4.78 SEK Jun 2024).
Outlook and guidance
Next report expected to show investment-related income as the new strategy is implemented.
Ambition to present first long-term portfolio investments in the second half of 2025.
Cost base significantly reduced, aiming for a positive financial result in the next period, adjusted for a one-time severance cost of 2.2 MSEK.
Latest events from Lärkberget
- Shifted to investment focus, posted positive H2, and grew NAV per share to 3.08 SEK.LARK
Q4 202512 Feb 2026 - Strategic Partner A/S proposes a new board led by Luca Di Stefano for CombiGene.LARK
Investor Update13 Jun 2025 - Gene therapy focus sharpened, COZY prioritized, and cost cuts extend liquidity to 2026.LARK
Q3 202413 Jun 2025 - CG01 rights regained, CGT2 discontinued, COZY advanced; sales and cash declined year-over-year.LARK
Q2 202413 Jun 2025 - CombiGene halts R&D, posts SEK 44.9m loss, and shifts focus to investments or dividends.LARK
Q4 20245 Jun 2025